We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI Model Analyzes Patient Data to Diagnose Multiple Sclerosis With 90% Accuracy

By MedImaging International staff writers
Posted on 01 May 2025
Print article
Image: The new AI model improves MS diagnostics (Photo courtesy of 123RF)
Image: The new AI model improves MS diagnostics (Photo courtesy of 123RF)

Multiple sclerosis (MS) is a chronic inflammatory condition affecting the central nervous system. Most patients initially experience the relapsing-remitting form (RRMS), characterized by periods of symptom flare-ups followed by stability. Over time, many individuals transition to secondary progressive MS (SPMS), where symptoms gradually worsen without noticeable breaks. Identifying this transition is critical, as the two forms of MS require different treatment approaches. Currently, the diagnosis is typically made an average of three years after the transition begins, which can result in patients receiving treatments that are no longer effective. Now, a new artificial intelligence (AI) model can predict with 90 percent certainty which form of MS a patient has. This model enhances the likelihood of starting the correct treatment promptly, helping to slow disease progression.

The AI model, developed by researchers at Uppsala University (Uppsala, Sweden), synthesizes clinical data from over 22,000 patients in the Swedish MS Registry. The model is based on data routinely collected during regular healthcare visits, including neurological tests, magnetic resonance imaging (MRI) scans, and ongoing treatments. In a study published in Digital Medicine, the model was able to identify the transition to secondary progressive MS correctly or earlier than recorded in the patient's medical history in nearly 87 percent of cases, achieving an overall accuracy of around 90 percent. For patients, this means an earlier diagnosis, allowing for timely adjustments in treatment to slow the disease's progression. This also reduces the likelihood of patients receiving medications that are no longer effective. In the future, the model could be used to identify appropriate candidates for clinical trials, potentially leading to more effective and personalized treatment strategies.

“By recognizing patterns from previous patients, the model can determine whether a patient has the relapsing-remitting form or whether the disease has transitioned to secondary progressive MS,” said Kim Kultima, researcher at the Department of Medical Sciences, Uppsala University, who led the study. “What is unique about the model is that it also indicates how confident it is in each individual assessment. This means that the doctor will know how reliable the conclusion is and how confident the AI is in its assessment.”

Related Links:
Uppsala University

New
Pocket Fetal Doppler
CONTEC10C/CL
Portable Color Doppler Ultrasound Scanner
DCU10
New
Mobile X-Ray Machine
MARS 15 / 30
New
Prostate Cancer MRI Analysis Tool
DynaCAD Urology

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

MRI

view channel
Image: An MRI scan can reveal a heart’s functional age (Photo courtesy of 123RF)

New MRI Technique Reveals True Heart Age to Prevent Attacks and Strokes

Heart disease remains one of the leading causes of death worldwide. Individuals with conditions such as diabetes or obesity often experience accelerated aging of their hearts, sometimes by decades.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.